Editorial Comment on Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial